Ausgabe 10/2008
Inhalt (15 Artikel)
Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient
Kazuhide Tsuji, Toshitada Hamada, Akiko Uenaka, Hisashi Wada, Eiichi Sato, Midori Isobe, Kenji Asagoe, Osamu Yamasaki, Hiroshi Shiku, Gerd Ritter, Roger Murphy, Eric W. Hoffman, Lloyd J. Old, Eiichi Nakayama, Keiji Iwatsuki
IL-21 induces in vivo immune activation of NK cells and CD8+ T cells in patients with metastatic melanoma and renal cell carcinoma
Klaus Stensgaard Frederiksen, Dorthe Lundsgaard, Jeremy A. Freeman, Steven D. Hughes, Thomas L. Holm, Birte K. Skrumsager, Andreas Petri, Lasse T. Hansen, Grant A. McArthur, Ian D. Davis, Kresten Skak
Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages
Panagiotis Tsagozis, Fredrik Eriksson, Pavel Pisa
Gamma-IFN-inducible-lysosomal thiol reductase modulates acidic proteases and HLA class II antigen processing in melanoma
Oliver G. Goldstein, Laela M. Hajiaghamohseni, Shereen Amria, Kumaran Sundaram, Sakamuri V. Reddy, Azizul Haque
Immune, endocrine, and behavioral precursors to breast cancer recurrence: a case-control analysis
Lisa M. Thornton, Barbara L. Andersen, William E. Carson III
Generation of antigen-specific CTL responses using RGS1 mRNA transfected dendritic cells
Frank Grünebach, Stefanie Erndt, Maik Häntschel, Annkristin Heine, Peter Brossart
Lung cancer patients’ CD4+ T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells
Minu K. Srivastava, Jacobus J. Bosch, James A. Thompson, Bruce R. Ksander, Martin J. Edelman, Suzanne Ostrand-Rosenberg
The E75 HER2/neu peptide vaccine
Elizabeth A. Mittendorf, Jarrod P. Holmes, Sathibalan Ponniah, George E. Peoples
Combined modality immunotherapy and chemotherapy: a new perspective
Rupal Ramakrishnan, Scott Antonia, Dmitry I. Gabrilovich
Spontaneous immune responses to sporadic tumors: tumor-promoting, tumor-protective or both?
Karin E. de Visser
NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy
Karl-Johan Malmberg, Yenan T. Bryceson, Mattias Carlsten, Sandra Andersson, Andreas Björklund, Niklas K. Björkström, Bettina C. Baumann, Cyril Fauriat, Evren Alici, M. Sirac Dilber, Hans-Gustaf Ljunggren
Anti-angiogenesis: making the tumor vulnerable to the immune system
Arjan W. Griffioen
Dendritic cell vaccination and immune monitoring
E. H. J. G. Aarntzen, C. G. Figdor, G. J. Adema, C. J. A. Punt, I. J. M. de Vries
Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines
Tanja D. de Gruijl, Alfons J. M. van den Eertwegh, Herbert M. Pinedo, Rik J. Scheper